Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_2
5
56%
Ph phase_3
2
22%

Phase Distribution

2

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 32 (22.2%)

Trials by Status

completed778%
terminated222%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

NCT04454411
completedphase_2

CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery

NCT01587196
completedphase_1

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

NCT04828694
completedphase_3

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

NCT03232346
terminatedphase_2

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

NCT03113409
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04454411Phase 2

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Terminated
NCT01587196Phase 2

CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery

Completed
NCT04828694Phase 1

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Completed
NCT03232346Phase 3

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

Completed
NCT03113409Phase 2

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

Terminated
NCT00476242Phase 2

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

Completed
NCT01377610Phase 1

Improved Strategies for Outpatient Opioid Detoxification

Completed
NCT01556425Phase 2

The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

Completed
NCT01389167Phase 3

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9